4.6 Review

Recent trends in praziquantel nanoformulations for helminthiasis treatment

Journal

EXPERT OPINION ON DRUG DELIVERY
Volume 19, Issue 4, Pages 383-393

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2022.2051477

Keywords

Nanomedicine; nanotechnology; helminthiasis; schistosomiasis; parasitic diseases; nanoformulation; nanomaterials; oral formulation; pediatric formulation; drug discovery

Funding

  1. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2019/25905-2, 2020/01441-4]

Ask authors/readers for more resources

This review focuses on the use of various types of nanomaterials to improve the therapy of praziquantel, the main drug for treating infections caused by parasitic flatworms. Recent advances in PZQ nanoformulations are also described, aiming to overcome the limitations of conventional drugs.
Introduction Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues. Areas covered This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described. Expert opinion Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available